Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Journal for ImmunoTherapy of Cancer · 2023-11 · 11 (11) · e007353
DOI: 10.1136/jitc-2023-007353 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 29.11.2023. Verfasst von Todd M Bauer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Background
NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors.
Methods
Patients received NIS793 (0.3–1 mg/kg every 3 weeks (Q3W)) monotherapy; following evaluation of two dose levels, dose escalation continued with NIS793 plus spartalizumab (NIS793 0.3–30 mg/kg Q3W and spartalizumab 300 mg Q3W or NIS793 20–30 mg/kg every 2 weeks [Q2W] and spartalizumab 400 mg every 4 weeks (Q4W)). In dose expansion, patients with non-small cell lung cancer (NSCLC) resistant to prior anti-programmed death ligand 1 or patients with microsatellite stable colorectal cancer (MSS-CRC) were treated at the recommended dose for expansion (RDE).
Results
Sixty patients were treated in dose escalation, 11 with NIS793 monotherapy and 49 with NIS793 plus spartalizumab, and 60 patients were treated in dose expansion (MSS-CRC: n=40; NSCLC: n=20). No dose-limiting toxicities were observed. The RDE was established as NIS793 30 mg/kg (2100 mg) and spartalizumab 300 mg Q3W. Overall 54 (49.5%) patients experienced ≥1 treatment-related adverse event, most commonly rash (n=16; 13.3%), pruritus (n=10; 8.3%), and fatigue (n=9; 7.5%). Three partial responses were reported: one in renal cell carcinoma (NIS793 30 mg/kg Q2W plus spartalizumab 400 mg Q4W), and two in the MSS-CRC expansion cohort. Biomarker data showed evidence of target engagement through increased TGF-β/NIS793 complexes and depleted active TGF-β in peripheral blood. Gene expression analyses in tumor biopsies demonstrated decreased TGF-β target genes and signatures and increased immune signatures.
Conclusions
In patients with advanced solid tumors, proof of mechanism of NIS793 is supported by evidence of target engagement and TGF-β pathway inhibition. Trial registration number NCT02947165 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sarah Cannon Research Institute, Nashville, Tennessee, USA.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Lombardia, Italy.
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Oncology, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
- Department of Oncology and Hematology, Kantonsspital St Gallen, St. Gallen, Switzerland.
ORCID-Profile: Armando Santoro, Chia-Chi Lin, Anna Spreafico, Pierre-Eric Juif
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Bauer, T. M., Santoro, A., Lin, C. C., Garrido-Laguna, I., Joerger, M., Greil, R., Spreafico, A., Yau, T., Goebeler, M. E., Hütter-Krönke, M. L., Perotti, A., Juif, P. E., Lu, D., Barys, L., Cremasco, V., Pelletier, M., Evans, H., Fabre, C., & Doi, T. (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for ImmunoTherapy of Cancer, 11(11), e007353. https://doi.org/10.1136/jitc-2023-007353
Vancouver
Bauer TM, Santoro A, Lin CC, Garrido-Laguna I, Joerger M, Greil R, et al. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 2023;11(11):e007353. doi:10.1136/jitc-2023-007353
BibTeX
@article{Bauer2023,
author = {Bauer, Todd M and Santoro, Armando and Lin, Chia-Chi and Garrido-Laguna, Ignacio and Joerger, Markus and Greil, Richard and Spreafico, Anna and Yau, Thomas and Goebeler, Maria-Elisabeth and Hütter-Krönke, Marie Luise and Perotti, Antonella and Juif, Pierre-Eric and Lu, Darlene and Barys, Louise and Cremasco, Viviana and Pelletier, Marc and Evans, Helen and Fabre, Claire and Doi, Toshikiko},
title = {Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {11},
pages = {e007353},
doi = {10.1136/jitc-2023-007353}
}
EUVIMED